OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, ARN reports. The brokerage currently has a $0.75 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 5.46% from […]
